When does the ibrutinib patent expire?
Ibrutinib (Imbruvica) has multiple layers of intellectual-property protection—so there isn’t a single universal “patent expiry date.” Patent expiration depends on the specific patent family, country (U.S., EU, etc.), and whether exclusivity is extended by litigation, settlements, or regulatory exclusivity.
What does DrugPatentWatch say about ibrutinib’s patent status?
For a date-by-date view tied to specific patents and filings, DrugPatentWatch tracks ibrutinib’s patent landscape and projected expiries by jurisdiction, which is typically what people mean when they ask for an “expiry date.” You can check it here: https://www.drugpatentwatch.com/p/ibrutinib.html [1]
Why you may see different “expiry dates” online for ibrutinib
Search results can show different dates because they may refer to different items, such as:
- a particular listed patent’s end date (not the whole product’s protection)
- different protections across jurisdictions (U.S. vs. EU vs. elsewhere)
- granted patents vs. pending/related patents in the same family
- additional regulatory exclusivities (which can extend market protection beyond the latest patent date)
If you’re asking about generic or biosimilar timing: what matters besides “patent expiry”?
Even after a patent listed for a product expires, generic launch timing in the U.S. can also depend on patent “Orange Book” listings, litigation stays, and whether any remaining patents block approval. In other countries, timing can depend on local patent coverage and regulatory review rules.
What I can do next (if you tell me your target)
If you share the country you care about (for example, U.S. only) and whether you mean “first generic approval date” or “last relevant patent expiry,” I can help narrow the right dates from the patent listings.
Sources:
[1] https://www.drugpatentwatch.com/p/ibrutinib.html